Advertisement
Screener

Cumberland Pharmaceuticals Inc. (CPIX) Material Contracts, 2021

Cumberland Pharmaceuticals Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2021-11-12: Form 10-Q; Exhibit 10.1; Description Fourth Amendment to Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement, dated as of October 28, 2021, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank..
  • 2021-05-14: Form 8-K; Exhibit 10.16; Description Exhibit 10.16 dated May 14, 2021.
  • 2021-03-12: Form 10-K; Exhibit 10.15; Description Employment Agreement dated March 8, 2021, effective as of January 1, 2021, by and between James L. Herman and Cumberland Pharmaceuticals Inc..
  • 2021-03-12: Form 10-K; Exhibit 10.14; Description Employment Agreement dated March 8, 2021, effective as of January 1, 2021, by and between Michael P. Bonner and Cumberland Pharmaceuticals Inc..
FiledFormExhibitDescription
2021-11-1210-Q10.1Fourth Amendment to Revolving Credit Note and Fifth Amendment to Revolving Credit Loan Agreement, dated as of October 28, 2021, by and between Cumberland Pharmaceuticals Inc. and Pinnacle Bank.
2021-05-148-K10.16Exhibit 10.16 dated May 14, 2021
2021-03-1210-K10.15Employment Agreement dated March 8, 2021, effective as of January 1, 2021, by and between James L. Herman and Cumberland Pharmaceuticals Inc.
2021-03-1210-K10.14Employment Agreement dated March 8, 2021, effective as of January 1, 2021, by and between Michael P. Bonner and Cumberland Pharmaceuticals Inc.
2021-03-1210-K10.13Employment Agreement dated March 8, 2021, effective as of January 1, 2021, by and between Leo B. Pavliv and Cumberland Pharmaceuticals Inc.
2021-03-1210-K10.12Employment Agreement dated March 8, 2021, effective as of January 1, 2021, by and between Martin E. Cearnal and Cumberland Pharmaceuticals Inc.
2021-03-1210-K10.11Employment Agreement dated March 8, 2021, effective as of January 1, 2021, by and between A.J. Kazimi and Cumberland Pharmaceuticals Inc.

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
INOVIO PHARMACEUTICALS, INC. (INO)United States$0.125B-1.35
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Immuneering Corp (IMRX)United States$0.113B-12.51
Quantum Cyber N.V. (QUCY)$0.113B
MEDICINOVA INC (MNOV)United States$0.130B-6.04
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31